CellVax Therapeutics
Miami, US · Founded 2020 · Delaware corporation
Find your way into CellVax Therapeutics
158 people in our graph share verified history with the CellVax Therapeutics team — schools, employers, funds. One of them is your warm intro.
Rohit Sharmaunlockedknows Fernando Kreutz · together at University of Alberta (overlapped)
×6knows the team · via FGV - Fundação Getulio Vargas
×2knows the team · via University of Alberta
×2knows the team · via Federal University of Rio Grande do Sul
knows the team · via Amcham-Brasil
CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
Founders & leadership
CellVax Therapeutics was founded in 2020 by Fernando Kreutz.
FK
Fernando KreutzinFounder & CEO, Board of DirectorsFernando Kreutz holds a PhD in Biotechnology from the University of Alberta and an MD from the Federal University of Rio Grande do Sul. He is founder and CEO of CellVax Therapeutics, where he leads clinical development of personalized cancer immunotherapies, and brings over 25 years of experience in immunotherapy, cell therapy, and biotechnology commercialization across multiple therapeutic areas including oncology and vaccine development.
EV
Emerson von der GoltzinCFO, Board of DirectorsCFO at CellVax Therapeutics, Emerson von der Goltz is an investment banker with over 15 years in mergers and acquisitions, previously serving as a biotech CFO and ten-year member of an infrastructure equity fund investment committee, with expertise spanning corporate finance, debt raising, and financial modeling across pharmaceuticals, biotechnology, and renewable energy sectors.
Board
AS
Alberto SteinMedical Adviser, Board of Directors
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 1 round · 2024
▶$2.1MraisedOct 2024 · 1 investors · OtherRule 506(b)
▶$2.1MraisedOct 2024 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Fernando KreutzExecutive Officer, Director
- Alberto da Costa SteinDirector
- Offering amount
- $5M
- Amount sold
- $2.1M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlap
Dynavax NASDAQ: DVAX www.dynavax.com15 shared keywordsDynavax is a commercial-stage biopharmaceutical company that develops and commercializes vaccines against infectious diseases using its adjuvant technology. Its products target immunization and infectious disease prevention.
CancerVAX14 shared keywordsCancerVax develops cancer therapeutics using lipid nanoparticle technology in partnership with Cytiva. The company is focused on creating nanoparticle-based treatments for cancer patients.
Centivax10 shared keywordsCentivax is a biotechnology company developing broad-spectrum vaccines, including a universal influenza vaccine.
Imvax10 shared keywordsImvax is a clinical-stage biopharmaceutical company developing personalized immunotherapies aimed at treating solid tumors, including glioblastoma. Its platform draws on autologous, cell-based approaches to target cancer.
Abivax9 shared keywordsAbivax develops obefazimod, an orally administered small molecule drug candidate with a novel mechanism of action targeting microRNA biology to treat chronic inflammatory diseases including ulcerative colitis and Crohn's disease.
Vaccinex9 shared keywordsVaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer. It also offers a fusion protein and ActivMab antibody discovery technology for incorporating membrane proteins such as GPCRs and ion channels into poxviruses for antibody selection.
Companies competing with CellVax Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does CellVax Therapeutics do?
- CellVax Therapeutics is a clinical-stage company developing personalized cell-based cancer immunotherapy that converts a patient's own tumor cells into antigen-presenting "Tumor Presenting Cells" to trigger a multi-neoantigen immune response. Its lead product, FK-PC101, targets high-risk prostate cancer patients after prostatectomy, with a platform intended to extend to other solid tumors.
- Who founded CellVax Therapeutics?
- CellVax Therapeutics was founded by Fernando Kreutz in 2020.
- How much funding has CellVax Therapeutics raised?
- CellVax Therapeutics has disclosed $2.1M raised across 1 round.
- Where is CellVax Therapeutics headquartered?
- CellVax Therapeutics is headquartered in Miami, US.